tiprankstipranks
Trending News
More News >
CK Life Sciences International (Holdings), Inc. (HK:0775)
:0775

CK Life Sciences International (Holdings), Inc. (0775) AI Stock Analysis

Compare
3 Followers

Top Page

HK

CK Life Sciences International (Holdings), Inc.

(0775)

Rating:65Neutral
Price Target:
CK Life Sciences' overall stock score reflects its strong technical momentum and operational efficiency, despite facing significant challenges in profitability and valuation. The company's operational cash flows are a positive aspect, but the financial leverage and negative net income remain key risks. The absence of recent earnings call data or notable corporate events leaves the focus on these fundamental and technical factors.

CK Life Sciences International (Holdings), Inc. (0775) vs. iShares MSCI Hong Kong ETF (EWH)

CK Life Sciences International (Holdings), Inc. Business Overview & Revenue Model

Company DescriptionCK Life Sciences International (Holdings), Inc. (0775) is a biotechnology company that operates as a part of the CK Hutchison Group. It is primarily focused on the development and commercialization of pharmaceuticals, nutraceuticals, and agriculture-related products. The company engages in the research and production of a range of health supplements, pharmaceuticals, and agricultural products aimed at enhancing human health and agricultural productivity.
How the Company Makes MoneyCK Life Sciences International generates revenue through the development, production, and sale of pharmaceuticals, nutraceuticals, and agricultural products. The company's revenue streams include the sale of health supplements and pharmaceuticals, which are distributed through various retail and wholesale channels. Additionally, it earns from the agricultural sector by providing products that enhance crop yields and protect against pests. Strategic partnerships and collaborations with research institutions and industry partners also contribute to its revenue, allowing for shared resources in research and development, which can lead to new product innovations and market expansions.

CK Life Sciences International (Holdings), Inc. Financial Statement Overview

Summary
CK Life Sciences is facing profitability challenges with a negative net income in 2024 despite stable revenue growth. Operational efficiency has improved, but high leverage and a declining equity ratio raise financial stability concerns. Positive operating and free cash flows suggest some operational strength, yet the cash flow decline indicates potential cash management issues.
Income Statement
65
Positive
The company has shown a modest revenue growth of 3.75% from 2023 to 2024. However, it reported a negative net income in 2024, resulting in a net profit margin of -2.29%, indicating profitability challenges. The gross profit margin remained stable at 30.64%, and the EBIT margin improved to 14.18%, suggesting operational efficiency improvements despite bottom-line issues.
Balance Sheet
60
Neutral
The debt-to-equity ratio increased to 1.74, indicating a higher leverage, which could pose financial risks. The equity ratio decreased to 32.53%, reflecting a lower proportion of equity financing in the asset structure. ROE turned negative due to the net loss, highlighting the strain on shareholder returns.
Cash Flow
70
Positive
Operating cash flow remained positive, although it decreased by 31.23% from the previous year. Free cash flow declined by 30.74%, suggesting reduced excess cash for reinvestment. The free cash flow to net income ratio is not meaningful due to the negative net income, but the company maintained a positive free cash flow.
BreakdownDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue5.52B5.32B5.28B5.40B4.94B
Gross Profit1.69B1.64B1.63B1.63B1.41B
EBITDA337.27M624.75M469.51M449.14M353.62M
Net Income-126.55M17.25M131.96M162.80M125.23M
Balance Sheet
Total Assets10.79B11.25B11.27B11.73B11.98B
Cash, Cash Equivalents and Short-Term Investments571.21M676.16M704.13M902.47M971.71M
Total Debt6.10B5.93B5.95B6.21B6.19B
Total Liabilities7.28B7.06B7.11B7.23B7.26B
Stockholders Equity3.51B4.19B4.16B4.50B4.72B
Cash Flow
Free Cash Flow154.06M222.35M146.69M206.33M151.12M
Operating Cash Flow353.53M514.18M363.66M423.57M530.96M
Investing Cash Flow-96.64M-67.96M-22.12M-257.88M-457.31M
Financing Cash Flow-341.98M-477.95M-515.34M-220.08M168.74M

CK Life Sciences International (Holdings), Inc. Technical Analysis

Technical Analysis Sentiment
Neutral
Last Price0.87
Price Trends
50DMA
0.87
Negative
100DMA
0.72
Positive
200DMA
0.58
Positive
Market Momentum
MACD
<0.01
Positive
RSI
50.15
Neutral
STOCH
38.10
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:0775, the sentiment is Neutral. The current price of 0.87 is below the 20-day moving average (MA) of 0.87, above the 50-day MA of 0.87, and above the 200-day MA of 0.58, indicating a neutral trend. The MACD of <0.01 indicates Positive momentum. The RSI at 50.15 is Neutral, neither overbought nor oversold. The STOCH value of 38.10 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for HK:0775.

CK Life Sciences International (Holdings), Inc. Peers Comparison

Overall Rating
UnderperformOutperform
Sector (59)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
65
Neutral
HK$8.36B-3.29%3.76%-833.33%
62
Neutral
HK$8.43B223.734.16%34.39%
59
Neutral
HK$15.36B5.63-7.44%4.08%11.55%-28.15%
57
Neutral
HK$8.45B-13.97%-97.81%-117.20%
55
Neutral
HK$7.31B-8.04%66.72%33.68%
46
Neutral
HK$6.82B272.762.28%-57.55%-87.49%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
HK:0775
CK Life Sciences International (Holdings), Inc.
0.86
0.52
152.94%
HK:2315
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H
21.70
14.25
191.28%
HK:2142
HBM Holdings Ltd.
7.92
6.61
504.58%
HK:1672
Ascletis Pharma, Inc.
8.89
7.89
789.00%
HK:1477
Ocumension Therapeutics
8.90
2.10
30.88%

CK Life Sciences International (Holdings), Inc. Corporate Events

CK Life Sciences Secures Strong Shareholder Support at AGM
May 22, 2025

CK Life Sciences International (Holdings) Inc. successfully conducted its Annual General Meeting on May 22, 2025, where all proposed resolutions were passed with overwhelming support. The resolutions included the approval of the audited financial statements for 2024, the election of directors, the appointment of auditors, and the granting of mandates to issue and buy back shares. This outcome reinforces the company’s governance structure and operational strategy, potentially strengthening its market position and shareholder confidence.

CK Life Sciences Enhances Governance with Updated Nomination Committee Terms
May 22, 2025

CK Life Sciences International (Holdings) Inc. has outlined the terms of reference for its Nomination Committee, which was established to ensure effective corporate governance in compliance with the Hong Kong Stock Exchange’s Listing Rules. The committee is responsible for reviewing the board’s structure and composition, identifying and recommending director candidates, assessing director independence, and supporting board performance evaluations. These measures are designed to align the board’s capabilities with the company’s strategic goals and enhance shareholder value.

CK Life Sciences Strengthens Governance with New Audit Committee Terms
May 22, 2025

CK Life Sciences International (Holdings) Inc. has outlined the terms of reference for its Audit Committee, which plays a crucial role in overseeing the company’s financial reporting, risk management, and internal control systems. The Audit Committee is composed of non-executive directors, with a majority being independent, and is tasked with ensuring compliance with corporate governance standards. This announcement underscores the company’s commitment to maintaining robust governance practices, which is vital for stakeholder confidence and the company’s operational integrity.

CK Life Sciences Advances Cancer Vaccine Research with AI Collaboration
Apr 22, 2025

CK Life Sciences International (Holdings) Inc. announced its plans to present new data from preclinical studies of investigational cancer vaccines at the 2025 AACR Annual Meeting. The vaccines target proteins such as PRAME, PD-L1, B7-H3, and Claudin 6, which are associated with different cancers. The company is also making progress in developing an AI-powered platform to improve vaccine design. While the preclinical results are promising, the company has not yet commenced clinical trials, and stakeholders are advised to exercise caution.

CK Life Sciences Announces 2025 AGM with Key Resolutions
Apr 15, 2025

CK Life Sciences International (Holdings) Inc. has announced its upcoming Annual General Meeting (AGM) scheduled for May 22, 2025, which will be held as a hybrid meeting both in-person and online. Key agenda items include the election of directors, appointment of auditors, and a resolution to grant the directors a mandate to issue additional shares, not exceeding ten percent of the current issued shares, with specific conditions on pricing and issuance period. This meeting is crucial for stakeholders as it will determine the company’s strategic directions and governance for the coming year.

CK Life Sciences Reports Promising Preclinical Results for TROP2 Cancer Vaccines
Apr 11, 2025

CK Life Sciences International (Holdings) Inc. has announced promising preclinical results for its novel cancer vaccines targeting TROP2, a protein overexpressed in various aggressive cancers. The vaccines have shown impressive tumor growth inhibition in mice studies, particularly in breast and colorectal cancers, and the company aims to advance these vaccines into clinical trials. The potential commercialization of these vaccines could bring significant economic benefits, although clinical trials have not yet commenced, and patent approvals are pending.

CK Life Sciences Announces Trading Halt Pending Major Announcement
Apr 10, 2025

CK Life Sciences International (Holdings), Inc. has announced a trading halt of its shares on the Hong Kong Stock Exchange as of April 10, 2025, pending a forthcoming announcement. This move indicates a significant development within the company, potentially impacting its market position and stakeholder interests.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: May 01, 2025